| Xhance (fluticasone propionate intranasal spray) / OptiNose |
NCT01624662 / 2011-004887-31: Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device |
|
|
| Completed | 3 | 323 | US | Fluticasone propionate, OPN-375 | Optinose US Inc. | Bilateral Nasal Polyposis | 05/15 | 07/15 | | |
NCT01623310: 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device |
|
|
| Completed | 3 | 223 | US | Fluticasone Propionate, OPN-375 | Optinose US Inc. | Nasal Polyps | 08/15 | 10/15 | | |
NCT01622569 / 2011-004886-34: Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety |
|
|
| Completed | 3 | 323 | Canada, US | Fluticasone Propionate, OPN-375 | Optinose US Inc. | Bilateral Nasal Polyposis | 08/15 | 10/15 | | |
NCT03591068: Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video |
|
|
| Completed | 3 | 11 | US | Fluticasone Propionate | Optinose US Inc. | Nasal Polyposis | 02/19 | 02/19 | | |
2019-000368-12: A 24-week study to find out if the nasal spray containing fluticasone propionate administered twice a day provides improvement and is safe for patients suffering from chronic sinusitis, and with or without nasal polyps. |
|
|
| Not yet recruiting | 3 | 378 | Europe | OptiNose Fluticasone, OPN-375, Nasal spray, suspension | OptiNose US, Inc., OptiNose US, Inc. | Chronic sinusitis, Chronic sinusitis, Diseases [C] - Ear, nose and throat diseases [C09] | | | | |
NCT03781804: Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps |
|
|
| Completed | 3 | 332 | Europe, Canada, US, RoW | OPN-375 | Optinose US Inc. | Chronic Rhinosinusitis | 01/22 | 01/22 | | |
| Completed | 3 | 223 | Europe, US, RoW | OPN-375 | Optinose US Inc. | Chronic Rhinosinusitis | 05/22 | 05/22 | | |
NCT03747458: OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps |
|
|
| Recruiting | 3 | 120 | US | OPN-375 | Optinose US Inc. | Bilateral Nasal Polyposis | 03/26 | 03/26 | | |
